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Sarcoidosis is a disease of unknown cause that primar-
ily involves the lungs and lymph nodes but is known 
also to involve the skin. liver. lacrimal glands, and 
potentially any organ or tissue in the body (I). The 
disease is characterized by the presence of noncaseating 
granuloma consisting of epithelioid cells and activated 
CD4 + T cells. 
Sarcoidosis can cause liver disease as well as hepa-
tosplenomegaly, presinusoidal ponal hypertension, and, 
rarely, a diffuse intrahepatic biliary disease similar to 
that seen In patients with primary sclerosing cholangitis 
(2). In addition to being a cause of liver disease. sar-
coidosis often coexists with other well-recognized liver 
diseases. such as primary hiliary cirrho"is. alcoholic 
liver disease. and postnecrotlc CirrhOSIS due to either 
chronic hepalilis B or hepatitis C virus Inkction. 
In either set ling. p:llIents Wllh sarCOIdOSIS become 
candidates tor liver transplantation as a consequence of 
end-stage liver disease. By necessity. liver transplanta-
tion IS followed by a lifelong reqUirement for Immuno-
suppressive therapy to prevent allograft rejection (3)_ 
Immunosuppression IS used also as pnmary treatment 
for patients with advanced symptomatic sarcoidosis and 
for those with disease involving the pulmonary paren-
chyma. myocardial conduction system. eyes. and cen-
tral nervous system. Studies suggest that such therapy 
is efficaCIOUs and prolongs life as well as organ function 
(4.9). The effects of liver transplantation and the subse· 
quent use of cyclosponne in patients with sarcoidOSIS 
have not been reported preVIously. We report our ex· 
perience with liver transplantation in 9 pallents with 
sarcoidOSIS and in 36 reCIpients wllhout sarcoidosis 
(18 with cholestallc liver disease and 18 with hepatocel-
lular disease I who were matched for age. gender. and 
time of liver transplantation. 
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Methods 
Patients 
From 1 January 1981 through 31 December 1991. nine 
adult patients with a diagnosis of sarcoidosis and with 
or without another cause of liver disease underwent 
orthotopic liver transplantation at the University of 
Pittsburgh. Their mean age was 45.1 ~ 2.8 years. Four 
were male and five were female. Their mean UNOS 
(United Network for Organ Sharing) score at the time 
of liver transplantation was 2.8 :!: 0_3. For each liver 
transplant reCIpient with sarcoidosis that was identified, 
four liver transplant recipients without sarcoidosis were 
identified who had undergone transplantation within 
30 days of the patient with sarcoidosis: In each case, 
two of the patients underwent transplantation because 
of a parenchymal (hepatocellular) liver disease (mean 
age. 45.3 ~ 1.9 years; UNOS score. 3.1 ~ 0.2), and two 
underwent transplantation because of a cholestatic liver 
disease (mean age. 43.8:!: 2.0 years; UNOS score, 
2.7 ~ 0.2). 
Chart Review 
The medical and surgical records of the nine patients 
with sarCOIdosis were reViewed to determlOe (he tissue 
~fles of sarcoid involvement. (he Cllurse uf sarCOIdOSIS 
after liver (ransplantatlon. and the post-transplant 
course :md prognosIs as assessed hy sl:nal anglo(ensln-
converting enzyme levels. pulmonary function (ests. 
and chest radIOgraphs. 
Statistical AnalySIS 
Life-table analysis for patient and graft survIval was 
carried out using the methods of Kaplan and Meier (10). 
The differences in survival hetween the patients with 
sarcoidosis and the (wo comparison groups were ana· 
Iyzed 00). 
Results 
The ':l pallents with sarcOldos(s. [he 18 pallents wnh 
cholestatlc liver dIsease (8 "'!th primary scleroSing 
cholangllls and 10 with primary biliary CIrrhOSIS I. and 
the 18 pallents with parenchymal liver disease 18 wl!h 
viral hepatitis. 8 with alcoholic liver disease. and 2 with 
cryptogenic liver disease) had similar demographic char. 
acteristics. None of the patients with parenchymal liver 
disease had hepatitis B. but eIght did have hepatitis C. 
Total bilirubin levels in the sarcoidosis. cholestatic 
disease. and parenchymal disease groups were 133.4 :!: 
25.7 ~mol/iK 295.8:!: 37.6 p.mol/L. and 35.9:: 5.1 
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J.l.mol/L, respectively; albumin levels were 27 - 4 gIL, 
.13 = 2 giL and 2J :: 4 giL, respectively: and pllJthrom-
hin times were 15.1 = 0.2 s, 13.1 = 0.2 s, and 17.3 = 
0.2 s, respectively. In each instance, Ii\ :r function mea-
surements for the sarcoidosis group fell midway between 
the measurements for the two comparison groups. 
In patients with sarcOIdosis, tissue involvement was 
demonstrated hlstu::>athologically. All nine patients had 
hepatic involvement; seven had pulmonary and medias-
tinal node involvement; three had lacrimal gland and 
skin involvement; and three had upper airway disease. 
The serum angiotensin-converting enzyme level and the 
peripheral blood helper (CD4+ l/suppressor (CD8+) cell 
ratio were determined before liver transplantation in all 
nine patients with sarcoidosis: The pallents had an ele-
vated angiotensin-converting enzyme level (mean, 
136 = 11 U) and a CD4+,CDS+ ratio of 1.9 = 0.2. All 
nine patients received cyclosporine. Graft and patient 
survival in the three groups is shown in Figure 1. No 
statistical difference between the three groups for either 
graft or patient survival was evident through 76 months 
(6.3 years). Although not significant, patient survival in 
the sarcoidosis group was anthmetically better through 
the first 5 years than that in the two companson groups. 
The three deaths that occurred in the sarcoidosis group 
at 6 years were caused by metastatic hepatocellular 
cancer; recurrent non-A, non-S hepatitis; and crypto-
genic cirrhosis. 
The most recent laboratory test results for the survivors 
in each group were normal. No eVldence of disease pro-
gression or continued disease activity was seen. The he-
patic disease in each case was eliminated by the total 
hepatectomy required as part of the liver transplant pro-
cedure. The lack of disease progression or continued dis-
ease activity involving the lungs. skin. and lacrimal glands 
reflects the intensity of the immunosuppressIVe therapy. 
DiscussioD 
Our retrospective study showed that patients with 
sarcoidosis who receive a liver allograft and are reo 
quired \0 take immunosuppressive agents at doses that 
prevent allograft rejection experience a remission of 
their sarcoidosis. These data confirm the beneficial ef-
forts of cyclosporine in patients with clinically active 
sarcoidosis and those with disease involVlng critical or-
gans (6-10). 
Our results. when combined with those from earlier 
series of patients with sarcoidosis who did not receive 
an organ allograft, define t/'te dose range within which 
patients with active sarcoidosis can be treated and their 
disease controlled completely without producing unac-
ceptable drug-associated toxicities. Such information is 
particularly imponant in patients with sarcoidosis, who 
may require prolonged immunosuppressive therapy. 
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